指南与共识重症综合管理与镇静镇痛创伤与烧伤

中重度创伤性脑损伤危重成人神经预后判断指南

Guidelines for Neuroprognostication in Critically Ill Adults with Moderate-Severe Traumatic Brain Injury.
指南 / 共识 · Neurocrit Care · 2024-02-17
一句话结论中重度创伤性脑损伤预后咨询中,仅双侧瞳孔无反应(入院时,准确评估且无药物/损伤干扰)及CRASH-basic、CRASH-CT、IMPACT-core、IMPACT-extended、IMPACT-lab模型具中等可靠性,使用时须告知不确定性。

该指南由神经重症监护学会(Neurocrit Care)发布,采用GRADE方法系统评价中重度创伤性脑损伤(msTBI)神经预后判断的临床预测因子和预测模型。筛查8125篇文献后纳入41篇,评估10个临床变量和9个评分量表。结果显示,仅入院时双侧瞳孔无反应(在准确评估且无药物或损伤干扰的条件下)对6个月功能结局或院内死亡率的预测具中等可靠性;CRASH-basic、CRASH-CT、IMPACT-core、IMPACT-extended和IMPACT-lab模型对14天至6个月死亡率及6个月及以上功能结局的预测具中等可靠性。使用这些中等可靠性预测因子或模型时,临床医生必须承认预后存在「实质性」不确定性。

要点

  • 入院时双侧瞳孔无反应(准确评估且无药物或损伤干扰)是唯一被认定为中等可靠的临床预测因子,用于向代理人咨询6个月功能结局或院内死亡率。
  • CRASH-basic、CRASH-CT、IMPACT-core、IMPACT-extended和IMPACT-lab模型被推荐为中等可靠,用于预测14天至6个月死亡率及6个月及以上功能结局。
  • 使用上述「中等可靠」预测因子或模型时,临床医生必须承认预后存在「实质性」不确定性。
  • 许多临床变量与msTBI不良结局相关,但仅双侧瞳孔无反应被认定为中等可靠用于预后咨询。
  • 指南提供了神经预后判断的关键原则性良好实践建议,并建议广泛原则。

适用人群与场景

  • 中重度创伤性脑损伤(msTBI)危重成人患者,用于向代理人进行预后咨询。

诊断标准与关键阈值

  • 预后判断中「不良」功能结局统一按「不利」结局处理,因文献定义不一。
  • 双侧瞳孔无反应需在入院时准确评估,且无药物或损伤干扰的条件下判定。

处置流程与药物剂量

  • 向代理人咨询6个月功能结局或院内死亡率时,可依据入院时双侧瞳孔无反应(条件为准确评估且无药物或损伤干扰)进行预后判断。
  • 预测14天至6个月死亡率及6个月及以上功能结局时,可使用CRASH-basic、CRASH-CT、IMPACT-core、IMPACT-extended和IMPACT-lab模型。
  • 使用上述中等可靠预测因子或模型时,必须向代理人说明预后存在「实质性」不确定性。

研究设计与关键结果

  • 系统筛查8125篇文献,41篇符合纳入标准,评估10个临床变量和9个评分量表。
  • 仅入院时双侧瞳孔无反应(准确评估且无药物或损伤干扰)被认定为中等可靠,用于咨询6个月功能结局或院内死亡率。
  • CRASH-basic、CRASH-CT、IMPACT-core、IMPACT-extended和IMPACT-lab模型被推荐为中等可靠,预测14天至6个月死亡率及6个月及以上功能结局。
  • 许多临床变量与msTBI不良结局相关,但多数可靠性不足。

证据类型、等级与局限

  • 证据类型:指南,采用GRADE方法进行系统叙述性综述。
  • 证据分级体系:GRADE,聚焦证据质量、结局意愿性、价值观与偏好、资源利用四项标准。

对床旁实践的改变

  • 在向msTBI患者代理人咨询预后时,可参考本指南对预测因子和模型正式可靠性的推荐。
  • 使用中等可靠预测因子或模型时,临床医生必须承认预后存在「实质性」不确定性。
  • 作者建议广泛遵循神经预后判断的基本原则。

指南或共识出处

  • 指南名称:Guidelines for Neuroprognostication in Critically Ill Adults with Moderate-Severe Traumatic Brain Injury;发布机构:Neurocrit Care;年份:原文未提供。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Moderate-severe traumatic brain injury (msTBI) carries high morbidity and mortality worldwide. Accurate neuroprognostication is essential in guiding clinical decisions, including patient triage and transition to comfort measures. Here we provide recommendations regarding the reliability of major clinical predictors and prediction models commonly used in msTBI neuroprognostication, guiding clinicians in counseling surrogate decision-makers.

METHODS: Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology, we conducted a systematic narrative review of the most clinically relevant predictors and prediction models cited in the literature. The review involved framing specific population/intervention/comparator/outcome/timing/setting (PICOTS) questions and employing stringent full-text screening criteria to examine the literature, focusing on four GRADE criteria: quality of evidence, desirability of outcomes, values and preferences, and resource use. Moreover, good practice recommendations addressing the key principles of neuroprognostication were drafted.

RESULTS: After screening 8125 articles, 41 met our eligibility criteria. Ten clinical variables and nine grading scales were selected. Many articles varied in defining "poor" functional outcomes. For consistency, we treated "poor" as "unfavorable". Although many clinical variables are associated with poor outcome in msTBI, only the presence of bilateral pupillary nonreactivity on admission, conditional on accurate assessment without confounding from medications or injuries, was deemed moderately reliable for counseling surrogates regarding 6-month functional outcomes or in-hospital mortality. In terms of prediction models, the Corticosteroid Randomization After Significant Head Injury (CRASH)-basic, CRASH-CT (CRASH-basic extended by computed tomography features), International Mission for Prognosis and Analysis of Clinical Trials in TBI (IMPACT)-core, IMPACT-extended, and IMPACT-lab models were recommended as moderately reliable in predicting 14-day to 6-month mortality and functional outcomes at 6 months and beyond. When using "moderately reliable" predictors or prediction models, the clinician must acknowledge "substantial" uncertainty in the prognosis.

CONCLUSIONS: These guidelines provide recommendations to clinicians on the formal reliability of individual predictors and prediction models of poor outcome when counseling surrogates of patients with msTBI and suggest broad principles of neuroprognostication.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Muehlschlegel S, Rajajee V, Wartenberg KE, et al. Guidelines for Neuroprognostication in Critically Ill Adults with Moderate-Severe Traumatic Brain Injury. Neurocrit Care. 2024. PMID: 38366277. doi:10.1007/s12028-023-01902-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。